Daniel Stefan Strasser

Daniel Stefan Strasser

Auto-generated profile, based on publicly available information

Daniel Stefan Strasser

Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMartin H. Bolli
Martin H. Bolli
SAStefan Abele
Stefan Abele
CBChristoph Binkert
Christoph Binkert
RBRoberto Bravo
Roberto Bravo
SBStephan Buchmann
Stephan Buchmann
TWThomas Weller
Thomas Weller

1 May 2017 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MVMagali Vercauteren
Magali Vercauteren
FTFrederic Trensz
Frederic Trensz
APAnne Pasquali
Anne Pasquali
CCChristophe Cattaneo
Christophe Cattaneo
DSDaniel S. Strasser
Daniel S. Strasser
MCMartine Clozel
Martine Clozel
Endothelin (ET) receptor antagonists have been associated with fluid retention. It has been suggested that, of the two endothelin receptor subtypes, ETB receptors should not be blocked, because of their involvement in natriuresis and diuresis. Surprisingly, clinical data suggest that ETA-selective antagonists pose a greater risk of fluid overload than dual antagonists. The purpose of this study was to evaluate the contribution of each endothelin receptor to fluid retention and vascular permeability in rats. Sitaxentan and ambrisentan as ETA-selective antagonists and bosentan and macitentan as dual antagonists were used as representatives of each class, respectively. ETA-selective antagonism caused a dose-dependent hematocrit/hemoglobin decrease that was prevented by ETB-selective receptor antagonism. ETA-selective antagonism led to a significant blood pressure reduction, plasma volume expansion, and a greater increase in vascular permeability than dual antagonism. Isolated vessel experiments showed that ETA-selective antagonism increased vascular permeability via ETB receptor overstimulation. Acutely, ETA-selective but not dual antagonism activated sympathetic activity and increased plasma arginine vasopressin and aldosterone concentrations. The hematocrit/hemoglobin decrease induced by ETA-selective antagonism was reduced in Brattleboro rats and in Wistar rats treated with an arginine vasopressin receptor antagonist. Finally, the decrease in hematocrit/hemoglobin was larger in the venous than in the arterial side, suggesting fluid redistribution. In conclusion, by activating ETB receptors, endothelin receptor antagonists (particularly ETA-selective antagonists) favor edema formation by causing: 1) fluid retention resulting from arginine vasopressin and aldosterone activation secondary to vasodilation, and 2) increased vascular permeability. Plasma volume redistribution may explain the clinical observation of a hematocrit/hemoglobin decrease even in the absence of signs of fluid retention.

16 June 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
PBPeter Bauer
Peter Bauer
DBDavid Balding
David Balding
HKHans H. Klünemann
Hans H. Klünemann
DLDavid E. J. Linden
David E. J. Linden
DODaniel S. Ory
Daniel S. Ory
MPMarc C. Patterson
Marc C. Patterson
Niemann–Pick disease type C (NP-C) is a rare, autosomal-recessive, progressive neurological disease caused by mutations in either the NPC1 gene (in 95% of cases) or the NPC2 gene. This observational, multicentre genetic screening study evaluated the frequency and phenotypes of NP-C in consecutive adult patients with neurological and psychiatric symptoms. Diagnostic testing for NP-C involved NPC1 and NPC2 exonic gene sequencing and gene dosage analysis. When available, results of filipin staining, plasma cholestane-3β,5α,6β-triol assays and measurements of relevant sphingolipids were also collected. NPC1 and NPC2 gene sequencing was completed in 250/256 patients from 30 psychiatric and neurological reference centres across the EU and USA [median (range) age 38 (18–90) years]. Three patients had a confirmed diagnosis of NP-C; two based on gene sequencing alone (two known causal disease alleles) and one based on gene sequencing and positive filipin staining. A further 12 patients displayed either single mutant NP-C alleles (8 with NPC1 mutations and 3 with NPC2 mutations) or a known causal disease mutation and an unclassified NPC1 allele variant (1 patient). Notably, high plasma cholestane-3β,5α,6β-triol levels were observed for all NP-C cases (n = 3). Overall, the frequency of NP-C patients in this study [1.2% (95% CI; 0.3%, 3.5%)] suggests that there may be an underdiagnosed pool of NP-C patients among adults who share common neurological and psychiatric symptoms.

6 April 2016 in Allergy
Verified
Journal Article
Closed access
PDF file
IAI. Agache
I. Agache
DSD. S. Strasser
D. S. Strasser
AKA. Klenk
A. Klenk
CAC. Agache
C. Agache
HFH. Farine
H. Farine
CAC. A. Akdis
C. A. Akdis

15 November 2016 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ASAnna K. Stalder
Anna K. Stalder
DLDominik Lott
Dominik Lott
DSDaniel S. Strasser
Daniel S. Strasser
HCHans G. Cruz
Hans G. Cruz
AKAndreas Krause
Andreas Krause
JDJasper Dingemanse
Jasper Dingemanse

28 July 2010 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
SSSachin V. Shelke
Sachin V. Shelke
BCBrian Cutting
Brian Cutting
XJXiaohua Jiang
Xiaohua Jiang
HKHendrik Koliwer‐Brandl
Hendrik Koliwer‐Brandl
DSDaniel S. Strasser
Daniel S. Strasser
BEBeat Ernst
Beat Ernst